Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines
Identifieur interne : 004F63 ( Main/Merge ); précédent : 004F62; suivant : 004F64Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines
Auteurs : Derrick Louz [Pays-Bas] ; Hans E. Bergmans [Pays-Bas] ; Birgit P. Loos [Pays-Bas] ; Rob C. Hoeben [Pays-Bas]Source :
- The Journal of Gene Medicine [ 1099-498X ] ; 2005-10.
Descripteurs français
- KwdFr :
- Animaux, Humains, Infections à VIH (transmission), Infections à VIH (virologie), Phénomènes physiologiques viraux, Recherche biomédicale (tendances), Risque, Techniques de transfert de gènes (effets indésirables), Thérapie génétique (effets indésirables), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (génétique), Vaccins atténués (effets indésirables), Vaccins atténués (génétique), Vecteurs génétiques (effets indésirables), Virus de la grippe A (génétique), Virus à ADN (génétique), Virus à ADN (physiologie), Virus à ARN (génétique), Virus à ARN (physiologie), Zoonoses (virologie), Évolution moléculaire.
- MESH :
- effets indésirables : Techniques de transfert de gènes, Thérapie génétique, Vaccins antiviraux, Vaccins atténués, Vecteurs génétiques.
- génétique : Vaccins antiviraux, Vaccins atténués, Virus de la grippe A, Virus à ADN, Virus à ARN.
- physiologie : Virus à ADN, Virus à ARN.
- tendances : Recherche biomédicale.
- virologie : Animaux, Humains, Infections à VIH, Phénomènes physiologiques viraux, Risque, Zoonoses, Évolution moléculaire.
English descriptors
- KwdEn :
- Animals, Biomedical Research (trends), DNA Viruses (genetics), DNA Viruses (physiology), Evolution, Molecular, Gene Transfer Techniques (adverse effects), Genetic Therapy (adverse effects), Genetic Vectors (adverse effects), HIV Infections (transmission), HIV Infections (virology), Humans, Influenza A virus (genetics), RNA Viruses (genetics), RNA Viruses (physiology), Risk, Vaccines, Attenuated (adverse effects), Vaccines, Attenuated (genetics), Viral Vaccines (adverse effects), Viral Vaccines (genetics), Virus Physiological Phenomena, Zoonoses (virology).
- MESH :
- chemical , adverse effects : Vaccines, Attenuated, Viral Vaccines.
- adverse effects : Gene Transfer Techniques, Genetic Therapy, Genetic Vectors.
- genetics : DNA Viruses, Influenza A virus, RNA Viruses, Vaccines, Attenuated, Viral Vaccines.
- physiology : DNA Viruses, RNA Viruses.
- transmission : HIV Infections.
- trends : Biomedical Research.
- virology : HIV Infections, Zoonoses.
- Teeft :
- Acad, Acid substitutions, Adenoviral, Adenoviral vectors, Adenovirus, Adenovirus type, Adenovirus vector, Alphaherpesvirus entry, Alternative receptors, Amino acid substitutions, Animal reservoirs, Animal viruses, Animals, Antigenic, Antigenic drift, Antigenic shift, Antigenic variants, Attenuated, Avian, Avian virus, Avian viruses, Biol, Biological properties, Biomedical research, Canine, Canine parvovirus, Canine transferrin receptor, Capsid, Cell culture, Cell cultures, Cell recognition, Cell tropism, Cellular environments, Cleavage site, Copyright, Coronavirus, Coronaviruses, Crossspecies transfer, Different cell types, Different strains, Disease virus, Ecological niches, Emergence, Evolution, Molecular, Experimental conditions, Experimental gene therapy, Feline, Feline cells, Feline host range, Further adaptation, Gene, Gene constellation, Gene segments, Gene therapy, Gene therapy progress, Genetic, Genetic changes, Genetic variants, Genetic variation, Genetics, Genetics systems, Genome, Glycoprotein, Haemorrhagic fever viruses, Hendra viruses, Heparan sulfate, Hong kong, Host cells, Host range, Host species, Human adenovirus, Human adenovirus type, Human population, Humans, Infectious diseases, Initial appearance, John wiley sons, Kawaoka, Large quantities, Lond, Louz, Mammalian host, Master sequence, Microbiol, Molecular basis, Molecular biology, Monkey cells, Monkeypox virus, Mouse hepatitis virus, Murine, Murine cells, Mutant, Mutation, Oncolytic viruses, Pandemic, Pandemic strain, Pandemic strains, Pandemic threat, Pandemic virus, Parvovirus, Passaging, Pathogenic viruses, Penton base, Permanent establishment, Persistent infection, Philos, Philos trans, Point mutations, Possible risks, Proc natl acad, Prominent examples, Pseudorabies virus, Receptor, Recombinant, Recombination, Relative risk, Replication, Respiratory syndrome, Restriction transgene, Risk, Risk assessments, Risk factors, Selective forces, Selective pressures, Sooty mangabeys, Species barrier, Substitution, Subtypes, Such activities, Such viruses, Surface glycoproteins, Surface proteins, Tissue tropism, Trans, Trends microbiol, Tropism, Vaccine, Vaccine strain, Variant, Vector viruses, Viral, Viral diseases, Viral gene transfer vectors, Viral genes, Viral infections, Viral life cycle, Viral vectors, Virol, Virology, Virus, Virus Physiological Phenomena, Virus vaccines, Virus variants, West africa, West nile virus, Western hemisphere, Yellow fever virus.
Abstract
All living organisms are continuously exposed to a plethora of viruses. In general, viruses tend to be restricted to the natural host species which they infect. From time to time viruses cross the host‐range barrier expanding their host range. However, in very rare cases cross‐species transfer is followed by the establishment and persistence of a virus in the new host species, which may result in disease. Recent examples of viruses that have crossed the species barrier from animal reservoirs to humans are hantavirus, haemorrhagic fever viruses, arboviruses, Nipah and Hendra viruses, avian influenza virus (AI), monkeypox virus, and the SARS‐associated coronavirus (SARS‐CoV). The opportunities for cross‐species transfer of mammalian viruses have increased in recent years due to increased contact between humans and animal reservoirs. However, it is difficult to predict when such events will take place since the viral adaptation that is needed to accomplish this is multifactorial and stochastic. Against this background the intensified use of viruses and their genetically modified variants as viral gene transfer vectors for biomedical research, experimental gene therapy and for live‐vector vaccines is a cause for concern. This review addresses a number of potential risk factors and their implications for activities with viral vectors from the perspective of cross‐species transfer of viruses in nature, with emphasis on the occurrence of host‐range mutants resulting from either cell culture or tropism engineering. The issues are raised with the intention to assist in risk assessments for activities with vector viruses. Copyright © 2005 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/jgm.794
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000963
- to stream Istex, to step Curation: 000963
- to stream Istex, to step Checkpoint: 001A96
- to stream PubMed, to step Corpus: 002665
- to stream PubMed, to step Curation: 002665
- to stream PubMed, to step Checkpoint: 002769
- to stream Ncbi, to step Merge: 001032
- to stream Ncbi, to step Curation: 001032
- to stream Ncbi, to step Checkpoint: 001032
Links to Exploration step
ISTEX:68727C717933CC66C3D46BC3B6AA113076DF9B28Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines</title>
<author><name sortKey="Louz, Derrick" sort="Louz, Derrick" uniqKey="Louz D" first="Derrick" last="Louz">Derrick Louz</name>
</author>
<author><name sortKey="Bergmans, Hans E" sort="Bergmans, Hans E" uniqKey="Bergmans H" first="Hans E." last="Bergmans">Hans E. Bergmans</name>
</author>
<author><name sortKey="Loos, Birgit P" sort="Loos, Birgit P" uniqKey="Loos B" first="Birgit P." last="Loos">Birgit P. Loos</name>
</author>
<author><name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:68727C717933CC66C3D46BC3B6AA113076DF9B28</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/jgm.794</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-CMJWR83W-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000963</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000963</idno>
<idno type="wicri:Area/Istex/Curation">000963</idno>
<idno type="wicri:Area/Istex/Checkpoint">001A96</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A96</idno>
<idno type="wicri:doubleKey">1099-498X:2005:Louz D:cross:species:transfer</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15986492</idno>
<idno type="wicri:Area/PubMed/Corpus">002665</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002665</idno>
<idno type="wicri:Area/PubMed/Curation">002665</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002665</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002769</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002769</idno>
<idno type="wicri:Area/Ncbi/Merge">001032</idno>
<idno type="wicri:Area/Ncbi/Curation">001032</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001032</idno>
<idno type="wicri:doubleKey">1099-498X:2005:Louz D:cross:species:transfer</idno>
<idno type="wicri:Area/Main/Merge">004F63</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines</title>
<author><name sortKey="Louz, Derrick" sort="Louz, Derrick" uniqKey="Louz D" first="Derrick" last="Louz">Derrick Louz</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre (SEC) of the National Institute of Public Health and the Environment (RIVM), Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Pays-Bas</country>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Correspondence address: RIVM/SEC/SMO Office, P.O. Box 1, 3720 BA Bilthoven</wicri:regionArea>
<wicri:noRegion>3720 BA Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bergmans, Hans E" sort="Bergmans, Hans E" uniqKey="Bergmans H" first="Hans E." last="Bergmans">Hans E. Bergmans</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre (SEC) of the National Institute of Public Health and the Environment (RIVM), Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Loos, Birgit P" sort="Loos, Birgit P" uniqKey="Loos B" first="Birgit P." last="Loos">Birgit P. Loos</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre (SEC) of the National Institute of Public Health and the Environment (RIVM), Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Molecular Cell Biology, Leiden University Medical Centre, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">The Journal of Gene Medicine</title>
<title level="j" type="alt">JOURNAL OF GENE MEDICINE, THE</title>
<idno type="ISSN">1099-498X</idno>
<idno type="eISSN">1521-2254</idno>
<imprint><biblScope unit="vol">7</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1263">1263</biblScope>
<biblScope unit="page" to="1274">1274</biblScope>
<biblScope unit="page-count">12</biblScope>
<publisher>John Wiley & Sons, Ltd.</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2005-10">2005-10</date>
</imprint>
<idno type="ISSN">1099-498X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1099-498X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Biomedical Research (trends)</term>
<term>DNA Viruses (genetics)</term>
<term>DNA Viruses (physiology)</term>
<term>Evolution, Molecular</term>
<term>Gene Transfer Techniques (adverse effects)</term>
<term>Genetic Therapy (adverse effects)</term>
<term>Genetic Vectors (adverse effects)</term>
<term>HIV Infections (transmission)</term>
<term>HIV Infections (virology)</term>
<term>Humans</term>
<term>Influenza A virus (genetics)</term>
<term>RNA Viruses (genetics)</term>
<term>RNA Viruses (physiology)</term>
<term>Risk</term>
<term>Vaccines, Attenuated (adverse effects)</term>
<term>Vaccines, Attenuated (genetics)</term>
<term>Viral Vaccines (adverse effects)</term>
<term>Viral Vaccines (genetics)</term>
<term>Virus Physiological Phenomena</term>
<term>Zoonoses (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Infections à VIH (transmission)</term>
<term>Infections à VIH (virologie)</term>
<term>Phénomènes physiologiques viraux</term>
<term>Recherche biomédicale (tendances)</term>
<term>Risque</term>
<term>Techniques de transfert de gènes (effets indésirables)</term>
<term>Thérapie génétique (effets indésirables)</term>
<term>Vaccins antiviraux (effets indésirables)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins atténués (effets indésirables)</term>
<term>Vaccins atténués (génétique)</term>
<term>Vecteurs génétiques (effets indésirables)</term>
<term>Virus de la grippe A (génétique)</term>
<term>Virus à ADN (génétique)</term>
<term>Virus à ADN (physiologie)</term>
<term>Virus à ARN (génétique)</term>
<term>Virus à ARN (physiologie)</term>
<term>Zoonoses (virologie)</term>
<term>Évolution moléculaire</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vaccines, Attenuated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Gene Transfer Techniques</term>
<term>Genetic Therapy</term>
<term>Genetic Vectors</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Techniques de transfert de gènes</term>
<term>Thérapie génétique</term>
<term>Vaccins antiviraux</term>
<term>Vaccins atténués</term>
<term>Vecteurs génétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>DNA Viruses</term>
<term>Influenza A virus</term>
<term>RNA Viruses</term>
<term>Vaccines, Attenuated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins atténués</term>
<term>Virus de la grippe A</term>
<term>Virus à ADN</term>
<term>Virus à ARN</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus à ADN</term>
<term>Virus à ARN</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>DNA Viruses</term>
<term>RNA Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Recherche biomédicale</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Biomedical Research</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Infections à VIH</term>
<term>Phénomènes physiologiques viraux</term>
<term>Risque</term>
<term>Zoonoses</term>
<term>Évolution moléculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term>
<term>Zoonoses</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Acad</term>
<term>Acid substitutions</term>
<term>Adenoviral</term>
<term>Adenoviral vectors</term>
<term>Adenovirus</term>
<term>Adenovirus type</term>
<term>Adenovirus vector</term>
<term>Alphaherpesvirus entry</term>
<term>Alternative receptors</term>
<term>Amino acid substitutions</term>
<term>Animal reservoirs</term>
<term>Animal viruses</term>
<term>Animals</term>
<term>Antigenic</term>
<term>Antigenic drift</term>
<term>Antigenic shift</term>
<term>Antigenic variants</term>
<term>Attenuated</term>
<term>Avian</term>
<term>Avian virus</term>
<term>Avian viruses</term>
<term>Biol</term>
<term>Biological properties</term>
<term>Biomedical research</term>
<term>Canine</term>
<term>Canine parvovirus</term>
<term>Canine transferrin receptor</term>
<term>Capsid</term>
<term>Cell culture</term>
<term>Cell cultures</term>
<term>Cell recognition</term>
<term>Cell tropism</term>
<term>Cellular environments</term>
<term>Cleavage site</term>
<term>Copyright</term>
<term>Coronavirus</term>
<term>Coronaviruses</term>
<term>Crossspecies transfer</term>
<term>Different cell types</term>
<term>Different strains</term>
<term>Disease virus</term>
<term>Ecological niches</term>
<term>Emergence</term>
<term>Evolution, Molecular</term>
<term>Experimental conditions</term>
<term>Experimental gene therapy</term>
<term>Feline</term>
<term>Feline cells</term>
<term>Feline host range</term>
<term>Further adaptation</term>
<term>Gene</term>
<term>Gene constellation</term>
<term>Gene segments</term>
<term>Gene therapy</term>
<term>Gene therapy progress</term>
<term>Genetic</term>
<term>Genetic changes</term>
<term>Genetic variants</term>
<term>Genetic variation</term>
<term>Genetics</term>
<term>Genetics systems</term>
<term>Genome</term>
<term>Glycoprotein</term>
<term>Haemorrhagic fever viruses</term>
<term>Hendra viruses</term>
<term>Heparan sulfate</term>
<term>Hong kong</term>
<term>Host cells</term>
<term>Host range</term>
<term>Host species</term>
<term>Human adenovirus</term>
<term>Human adenovirus type</term>
<term>Human population</term>
<term>Humans</term>
<term>Infectious diseases</term>
<term>Initial appearance</term>
<term>John wiley sons</term>
<term>Kawaoka</term>
<term>Large quantities</term>
<term>Lond</term>
<term>Louz</term>
<term>Mammalian host</term>
<term>Master sequence</term>
<term>Microbiol</term>
<term>Molecular basis</term>
<term>Molecular biology</term>
<term>Monkey cells</term>
<term>Monkeypox virus</term>
<term>Mouse hepatitis virus</term>
<term>Murine</term>
<term>Murine cells</term>
<term>Mutant</term>
<term>Mutation</term>
<term>Oncolytic viruses</term>
<term>Pandemic</term>
<term>Pandemic strain</term>
<term>Pandemic strains</term>
<term>Pandemic threat</term>
<term>Pandemic virus</term>
<term>Parvovirus</term>
<term>Passaging</term>
<term>Pathogenic viruses</term>
<term>Penton base</term>
<term>Permanent establishment</term>
<term>Persistent infection</term>
<term>Philos</term>
<term>Philos trans</term>
<term>Point mutations</term>
<term>Possible risks</term>
<term>Proc natl acad</term>
<term>Prominent examples</term>
<term>Pseudorabies virus</term>
<term>Receptor</term>
<term>Recombinant</term>
<term>Recombination</term>
<term>Relative risk</term>
<term>Replication</term>
<term>Respiratory syndrome</term>
<term>Restriction transgene</term>
<term>Risk</term>
<term>Risk assessments</term>
<term>Risk factors</term>
<term>Selective forces</term>
<term>Selective pressures</term>
<term>Sooty mangabeys</term>
<term>Species barrier</term>
<term>Substitution</term>
<term>Subtypes</term>
<term>Such activities</term>
<term>Such viruses</term>
<term>Surface glycoproteins</term>
<term>Surface proteins</term>
<term>Tissue tropism</term>
<term>Trans</term>
<term>Trends microbiol</term>
<term>Tropism</term>
<term>Vaccine</term>
<term>Vaccine strain</term>
<term>Variant</term>
<term>Vector viruses</term>
<term>Viral</term>
<term>Viral diseases</term>
<term>Viral gene transfer vectors</term>
<term>Viral genes</term>
<term>Viral infections</term>
<term>Viral life cycle</term>
<term>Viral vectors</term>
<term>Virol</term>
<term>Virology</term>
<term>Virus</term>
<term>Virus Physiological Phenomena</term>
<term>Virus vaccines</term>
<term>Virus variants</term>
<term>West africa</term>
<term>West nile virus</term>
<term>Western hemisphere</term>
<term>Yellow fever virus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">All living organisms are continuously exposed to a plethora of viruses. In general, viruses tend to be restricted to the natural host species which they infect. From time to time viruses cross the host‐range barrier expanding their host range. However, in very rare cases cross‐species transfer is followed by the establishment and persistence of a virus in the new host species, which may result in disease. Recent examples of viruses that have crossed the species barrier from animal reservoirs to humans are hantavirus, haemorrhagic fever viruses, arboviruses, Nipah and Hendra viruses, avian influenza virus (AI), monkeypox virus, and the SARS‐associated coronavirus (SARS‐CoV). The opportunities for cross‐species transfer of mammalian viruses have increased in recent years due to increased contact between humans and animal reservoirs. However, it is difficult to predict when such events will take place since the viral adaptation that is needed to accomplish this is multifactorial and stochastic. Against this background the intensified use of viruses and their genetically modified variants as viral gene transfer vectors for biomedical research, experimental gene therapy and for live‐vector vaccines is a cause for concern. This review addresses a number of potential risk factors and their implications for activities with viral vectors from the perspective of cross‐species transfer of viruses in nature, with emphasis on the occurrence of host‐range mutants resulting from either cell culture or tropism engineering. The issues are raised with the intention to assist in risk assessments for activities with vector viruses. Copyright © 2005 John Wiley & Sons, Ltd.</div>
</front>
</TEI>
<double doi="10.1002/jgm.794"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines</title>
<author><name sortKey="Louz, Derrick" sort="Louz, Derrick" uniqKey="Louz D" first="Derrick" last="Louz">Derrick Louz</name>
</author>
<author><name sortKey="Bergmans, Hans E" sort="Bergmans, Hans E" uniqKey="Bergmans H" first="Hans E." last="Bergmans">Hans E. Bergmans</name>
</author>
<author><name sortKey="Loos, Birgit P" sort="Loos, Birgit P" uniqKey="Loos B" first="Birgit P." last="Loos">Birgit P. Loos</name>
</author>
<author><name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:68727C717933CC66C3D46BC3B6AA113076DF9B28</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/jgm.794</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-CMJWR83W-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000963</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000963</idno>
<idno type="wicri:Area/Istex/Curation">000963</idno>
<idno type="wicri:Area/Istex/Checkpoint">001A96</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A96</idno>
<idno type="wicri:doubleKey">1099-498X:2005:Louz D:cross:species:transfer</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines</title>
<author><name sortKey="Louz, Derrick" sort="Louz, Derrick" uniqKey="Louz D" first="Derrick" last="Louz">Derrick Louz</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre (SEC) of the National Institute of Public Health and the Environment (RIVM), Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Pays-Bas</country>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Correspondence address: RIVM/SEC/SMO Office, P.O. Box 1, 3720 BA Bilthoven</wicri:regionArea>
<wicri:noRegion>3720 BA Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bergmans, Hans E" sort="Bergmans, Hans E" uniqKey="Bergmans H" first="Hans E." last="Bergmans">Hans E. Bergmans</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre (SEC) of the National Institute of Public Health and the Environment (RIVM), Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Loos, Birgit P" sort="Loos, Birgit P" uniqKey="Loos B" first="Birgit P." last="Loos">Birgit P. Loos</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre (SEC) of the National Institute of Public Health and the Environment (RIVM), Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Molecular Cell Biology, Leiden University Medical Centre, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">The Journal of Gene Medicine</title>
<title level="j" type="alt">JOURNAL OF GENE MEDICINE, THE</title>
<idno type="ISSN">1099-498X</idno>
<idno type="eISSN">1521-2254</idno>
<imprint><biblScope unit="vol">7</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1263">1263</biblScope>
<biblScope unit="page" to="1274">1274</biblScope>
<biblScope unit="page-count">12</biblScope>
<publisher>John Wiley & Sons, Ltd.</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2005-10">2005-10</date>
</imprint>
<idno type="ISSN">1099-498X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1099-498X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term>
<term>Acid substitutions</term>
<term>Adenoviral</term>
<term>Adenoviral vectors</term>
<term>Adenovirus</term>
<term>Adenovirus type</term>
<term>Adenovirus vector</term>
<term>Alphaherpesvirus entry</term>
<term>Alternative receptors</term>
<term>Amino acid substitutions</term>
<term>Animal reservoirs</term>
<term>Animal viruses</term>
<term>Antigenic</term>
<term>Antigenic drift</term>
<term>Antigenic shift</term>
<term>Antigenic variants</term>
<term>Attenuated</term>
<term>Avian</term>
<term>Avian virus</term>
<term>Avian viruses</term>
<term>Biol</term>
<term>Biological properties</term>
<term>Biomedical research</term>
<term>Canine</term>
<term>Canine parvovirus</term>
<term>Canine transferrin receptor</term>
<term>Capsid</term>
<term>Cell culture</term>
<term>Cell cultures</term>
<term>Cell recognition</term>
<term>Cell tropism</term>
<term>Cellular environments</term>
<term>Cleavage site</term>
<term>Copyright</term>
<term>Coronavirus</term>
<term>Coronaviruses</term>
<term>Crossspecies transfer</term>
<term>Different cell types</term>
<term>Different strains</term>
<term>Disease virus</term>
<term>Ecological niches</term>
<term>Emergence</term>
<term>Experimental conditions</term>
<term>Experimental gene therapy</term>
<term>Feline</term>
<term>Feline cells</term>
<term>Feline host range</term>
<term>Further adaptation</term>
<term>Gene</term>
<term>Gene constellation</term>
<term>Gene segments</term>
<term>Gene therapy</term>
<term>Gene therapy progress</term>
<term>Genetic</term>
<term>Genetic changes</term>
<term>Genetic variants</term>
<term>Genetic variation</term>
<term>Genetics</term>
<term>Genetics systems</term>
<term>Genome</term>
<term>Glycoprotein</term>
<term>Haemorrhagic fever viruses</term>
<term>Hendra viruses</term>
<term>Heparan sulfate</term>
<term>Hong kong</term>
<term>Host cells</term>
<term>Host range</term>
<term>Host species</term>
<term>Human adenovirus</term>
<term>Human adenovirus type</term>
<term>Human population</term>
<term>Infectious diseases</term>
<term>Initial appearance</term>
<term>John wiley sons</term>
<term>Kawaoka</term>
<term>Large quantities</term>
<term>Lond</term>
<term>Louz</term>
<term>Mammalian host</term>
<term>Master sequence</term>
<term>Microbiol</term>
<term>Molecular basis</term>
<term>Molecular biology</term>
<term>Monkey cells</term>
<term>Monkeypox virus</term>
<term>Mouse hepatitis virus</term>
<term>Murine</term>
<term>Murine cells</term>
<term>Mutant</term>
<term>Mutation</term>
<term>Oncolytic viruses</term>
<term>Pandemic</term>
<term>Pandemic strain</term>
<term>Pandemic strains</term>
<term>Pandemic threat</term>
<term>Pandemic virus</term>
<term>Parvovirus</term>
<term>Passaging</term>
<term>Pathogenic viruses</term>
<term>Penton base</term>
<term>Permanent establishment</term>
<term>Persistent infection</term>
<term>Philos</term>
<term>Philos trans</term>
<term>Point mutations</term>
<term>Possible risks</term>
<term>Proc natl acad</term>
<term>Prominent examples</term>
<term>Pseudorabies virus</term>
<term>Receptor</term>
<term>Recombinant</term>
<term>Recombination</term>
<term>Relative risk</term>
<term>Replication</term>
<term>Respiratory syndrome</term>
<term>Restriction transgene</term>
<term>Risk assessments</term>
<term>Risk factors</term>
<term>Selective forces</term>
<term>Selective pressures</term>
<term>Sooty mangabeys</term>
<term>Species barrier</term>
<term>Substitution</term>
<term>Subtypes</term>
<term>Such activities</term>
<term>Such viruses</term>
<term>Surface glycoproteins</term>
<term>Surface proteins</term>
<term>Tissue tropism</term>
<term>Trans</term>
<term>Trends microbiol</term>
<term>Tropism</term>
<term>Vaccine</term>
<term>Vaccine strain</term>
<term>Variant</term>
<term>Vector viruses</term>
<term>Viral</term>
<term>Viral diseases</term>
<term>Viral gene transfer vectors</term>
<term>Viral genes</term>
<term>Viral infections</term>
<term>Viral life cycle</term>
<term>Viral vectors</term>
<term>Virol</term>
<term>Virology</term>
<term>Virus</term>
<term>Virus vaccines</term>
<term>Virus variants</term>
<term>West africa</term>
<term>West nile virus</term>
<term>Western hemisphere</term>
<term>Yellow fever virus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">All living organisms are continuously exposed to a plethora of viruses. In general, viruses tend to be restricted to the natural host species which they infect. From time to time viruses cross the host‐range barrier expanding their host range. However, in very rare cases cross‐species transfer is followed by the establishment and persistence of a virus in the new host species, which may result in disease. Recent examples of viruses that have crossed the species barrier from animal reservoirs to humans are hantavirus, haemorrhagic fever viruses, arboviruses, Nipah and Hendra viruses, avian influenza virus (AI), monkeypox virus, and the SARS‐associated coronavirus (SARS‐CoV). The opportunities for cross‐species transfer of mammalian viruses have increased in recent years due to increased contact between humans and animal reservoirs. However, it is difficult to predict when such events will take place since the viral adaptation that is needed to accomplish this is multifactorial and stochastic. Against this background the intensified use of viruses and their genetically modified variants as viral gene transfer vectors for biomedical research, experimental gene therapy and for live‐vector vaccines is a cause for concern. This review addresses a number of potential risk factors and their implications for activities with viral vectors from the perspective of cross‐species transfer of viruses in nature, with emphasis on the occurrence of host‐range mutants resulting from either cell culture or tropism engineering. The issues are raised with the intention to assist in risk assessments for activities with vector viruses. Copyright © 2005 John Wiley & Sons, Ltd.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines.</title>
<author><name sortKey="Louz, Derrick" sort="Louz, Derrick" uniqKey="Louz D" first="Derrick" last="Louz">Derrick Louz</name>
<affiliation wicri:level="1"><nlm:affiliation>GMO Office, Substances Expertise Centre of the National Institute of Public Health and the Environment, Bilthoven, The Netherlands. derrick.louz@rivm.nl</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre of the National Institute of Public Health and the Environment, Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bergmans, Hans E" sort="Bergmans, Hans E" uniqKey="Bergmans H" first="Hans E" last="Bergmans">Hans E. Bergmans</name>
</author>
<author><name sortKey="Loos, Birgit P" sort="Loos, Birgit P" uniqKey="Loos B" first="Birgit P" last="Loos">Birgit P. Loos</name>
</author>
<author><name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C" last="Hoeben">Rob C. Hoeben</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15986492</idno>
<idno type="pmid">15986492</idno>
<idno type="doi">10.1002/jgm.794</idno>
<idno type="wicri:Area/PubMed/Corpus">002665</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002665</idno>
<idno type="wicri:Area/PubMed/Curation">002665</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002665</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002769</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002769</idno>
<idno type="wicri:Area/Ncbi/Merge">001032</idno>
<idno type="wicri:Area/Ncbi/Curation">001032</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001032</idno>
<idno type="wicri:doubleKey">1099-498X:2005:Louz D:cross:species:transfer</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines.</title>
<author><name sortKey="Louz, Derrick" sort="Louz, Derrick" uniqKey="Louz D" first="Derrick" last="Louz">Derrick Louz</name>
<affiliation wicri:level="1"><nlm:affiliation>GMO Office, Substances Expertise Centre of the National Institute of Public Health and the Environment, Bilthoven, The Netherlands. derrick.louz@rivm.nl</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>GMO Office, Substances Expertise Centre of the National Institute of Public Health and the Environment, Bilthoven</wicri:regionArea>
<wicri:noRegion>Bilthoven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bergmans, Hans E" sort="Bergmans, Hans E" uniqKey="Bergmans H" first="Hans E" last="Bergmans">Hans E. Bergmans</name>
</author>
<author><name sortKey="Loos, Birgit P" sort="Loos, Birgit P" uniqKey="Loos B" first="Birgit P" last="Loos">Birgit P. Loos</name>
</author>
<author><name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C" last="Hoeben">Rob C. Hoeben</name>
</author>
</analytic>
<series><title level="j">The journal of gene medicine</title>
<idno type="ISSN">1099-498X</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Biomedical Research (trends)</term>
<term>DNA Viruses (genetics)</term>
<term>DNA Viruses (physiology)</term>
<term>Evolution, Molecular</term>
<term>Gene Transfer Techniques (adverse effects)</term>
<term>Genetic Therapy (adverse effects)</term>
<term>Genetic Vectors (adverse effects)</term>
<term>HIV Infections (transmission)</term>
<term>HIV Infections (virology)</term>
<term>Humans</term>
<term>Influenza A virus (genetics)</term>
<term>RNA Viruses (genetics)</term>
<term>RNA Viruses (physiology)</term>
<term>Risk</term>
<term>Vaccines, Attenuated (adverse effects)</term>
<term>Vaccines, Attenuated (genetics)</term>
<term>Viral Vaccines (adverse effects)</term>
<term>Viral Vaccines (genetics)</term>
<term>Virus Physiological Phenomena</term>
<term>Zoonoses (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Infections à VIH (transmission)</term>
<term>Infections à VIH (virologie)</term>
<term>Phénomènes physiologiques viraux</term>
<term>Recherche biomédicale (tendances)</term>
<term>Risque</term>
<term>Techniques de transfert de gènes (effets indésirables)</term>
<term>Thérapie génétique (effets indésirables)</term>
<term>Vaccins antiviraux (effets indésirables)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins atténués (effets indésirables)</term>
<term>Vaccins atténués (génétique)</term>
<term>Vecteurs génétiques (effets indésirables)</term>
<term>Virus de la grippe A (génétique)</term>
<term>Virus à ADN (génétique)</term>
<term>Virus à ADN (physiologie)</term>
<term>Virus à ARN (génétique)</term>
<term>Virus à ARN (physiologie)</term>
<term>Zoonoses (virologie)</term>
<term>Évolution moléculaire</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vaccines, Attenuated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Gene Transfer Techniques</term>
<term>Genetic Therapy</term>
<term>Genetic Vectors</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Techniques de transfert de gènes</term>
<term>Thérapie génétique</term>
<term>Vaccins antiviraux</term>
<term>Vaccins atténués</term>
<term>Vecteurs génétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>DNA Viruses</term>
<term>Influenza A virus</term>
<term>RNA Viruses</term>
<term>Vaccines, Attenuated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins atténués</term>
<term>Virus de la grippe A</term>
<term>Virus à ADN</term>
<term>Virus à ARN</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus à ADN</term>
<term>Virus à ARN</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>DNA Viruses</term>
<term>RNA Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Recherche biomédicale</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Biomedical Research</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term>
<term>Zoonoses</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term>
<term>Zoonoses</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Evolution, Molecular</term>
<term>Humans</term>
<term>Risk</term>
<term>Virus Physiological Phenomena</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Infections à VIH</term>
<term>Phénomènes physiologiques viraux</term>
<term>Risque</term>
<term>Évolution moléculaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">All living organisms are continuously exposed to a plethora of viruses. In general, viruses tend to be restricted to the natural host species which they infect. From time to time viruses cross the host-range barrier expanding their host range. However, in very rare cases cross-species transfer is followed by the establishment and persistence of a virus in the new host species, which may result in disease. Recent examples of viruses that have crossed the species barrier from animal reservoirs to humans are hantavirus, haemorrhagic fever viruses, arboviruses, Nipah and Hendra viruses, avian influenza virus (AI), monkeypox virus, and the SARS-associated coronavirus (SARS-CoV). The opportunities for cross-species transfer of mammalian viruses have increased in recent years due to increased contact between humans and animal reservoirs. However, it is difficult to predict when such events will take place since the viral adaptation that is needed to accomplish this is multifactorial and stochastic. Against this background the intensified use of viruses and their genetically modified variants as viral gene transfer vectors for biomedical research, experimental gene therapy and for live-vector vaccines is a cause for concern. This review addresses a number of potential risk factors and their implications for activities with viral vectors from the perspective of cross-species transfer of viruses in nature, with emphasis on the occurrence of host-range mutants resulting from either cell culture or tropism engineering. The issues are raised with the intention to assist in risk assessments for activities with vector viruses.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004F63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:68727C717933CC66C3D46BC3B6AA113076DF9B28 |texte= Cross‐species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live‐virus vaccines }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |